Development of α-Synuclein Real-Time Quaking-Induced Conversion as a Diagnostic Method for α-Synucleinopathies
- PMID: 34650422
- PMCID: PMC8510559
- DOI: 10.3389/fnagi.2021.703984
Development of α-Synuclein Real-Time Quaking-Induced Conversion as a Diagnostic Method for α-Synucleinopathies
Abstract
Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy are characterized by aggregation of abnormal α-synuclein (α-syn) and collectively referred to as α-synucleinopathy. Because these diseases have different prognoses and treatments, it is desirable to diagnose them early and accurately. However, it is difficult to accurately diagnose these diseases by clinical symptoms because symptoms such as muscle rigidity, postural dysreflexia, and dementia sometimes overlap among these diseases. The process of conformational conversion and aggregation of α-syn has been thought similar to that of abnormal prion proteins that cause prion diseases. In recent years, in vitro conversion methods, such as real-time quaking-induced conversion (RT-QuIC), have been developed. This method has succeeded in amplifying and detecting trace amounts of abnormal prion proteins in tissues and central spinal fluid of patients by inducing conversion of recombinant prion proteins via shaking. Additionally, it has been used for antemortem diagnosis of prion diseases. Recently, aggregated α-syn has also been amplified and detected in patients by applying this method and many clinical studies have examined diagnosis using tissues or cerebral spinal fluid from patients. In this review, we discuss the utility and problems of α-syn RT-QuIC for antemortem diagnosis of α-synucleinopathies.
Keywords: Parkinson’s disease; RT-QuIC; antemortem diagnosis; dementia with Lewy bodies (DLB); multiple system atrophy (MSA); α-synuclein (α-syn).
Copyright © 2021 Nakagaki, Nishida and Satoh.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
Pathological α-synuclein detected by real-time quaking-induced conversion in synucleinopathies.Exp Gerontol. 2024 Mar;187:112366. doi: 10.1016/j.exger.2024.112366. Epub 2024 Feb 6. Exp Gerontol. 2024. PMID: 38280659 Review.
-
Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies.Acta Neuropathol. 2020 Jul;140(1):49-62. doi: 10.1007/s00401-020-02160-8. Epub 2020 Apr 27. Acta Neuropathol. 2020. PMID: 32342188 Free PMC article.
-
Ultrasensitive Detection of Aggregated α-Synuclein in Glial Cells, Human Cerebrospinal Fluid, and Brain Tissue Using the RT-QuIC Assay: New High-Throughput Neuroimmune Biomarker Assay for Parkinsonian Disorders.J Neuroimmune Pharmacol. 2019 Sep;14(3):423-435. doi: 10.1007/s11481-019-09835-4. Epub 2019 Jan 31. J Neuroimmune Pharmacol. 2019. PMID: 30706414 Free PMC article.
-
Misfolded alpha-synuclein detection by RT-QuIC in dementia with lewy bodies: a systematic review and meta-analysis.Front Mol Biosci. 2023 May 17;10:1193458. doi: 10.3389/fmolb.2023.1193458. eCollection 2023. Front Mol Biosci. 2023. PMID: 37266333 Free PMC article. Review.
-
Refining α-synuclein seed amplification assays to distinguish Parkinson's disease from multiple system atrophy.Transl Neurodegener. 2025 Feb 7;14(1):7. doi: 10.1186/s40035-025-00469-6. Transl Neurodegener. 2025. PMID: 39920796 Free PMC article.
Cited by
-
α-synuclein seed amplification assay sensitivity may be associated with cardiac MIBG abnormality among patients with Lewy body disease.NPJ Parkinsons Dis. 2024 Oct 21;10(1):190. doi: 10.1038/s41531-024-00806-y. NPJ Parkinsons Dis. 2024. PMID: 39433540 Free PMC article.
-
Blood-based biomarker in Parkinson's disease: potential for future applications in clinical research and practice.J Neural Transm (Vienna). 2022 Sep;129(9):1201-1217. doi: 10.1007/s00702-022-02498-1. Epub 2022 Apr 15. J Neural Transm (Vienna). 2022. PMID: 35428925 Free PMC article. Review.
-
α-Synuclein seed amplification technology for Parkinson's disease and related synucleinopathies.Trends Biotechnol. 2024 Jul;42(7):829-841. doi: 10.1016/j.tibtech.2024.01.007. Epub 2024 Feb 23. Trends Biotechnol. 2024. PMID: 38395703 Free PMC article. Review.
-
Alpha-Synuclein species in oral mucosa as potential biomarkers for multiple system atrophy.Front Aging Neurosci. 2022 Oct 11;14:1010064. doi: 10.3389/fnagi.2022.1010064. eCollection 2022. Front Aging Neurosci. 2022. PMID: 36304930 Free PMC article.
-
Multidimensional biomarkers for multiple system atrophy: an update and future directions.Transl Neurodegener. 2023 Jul 28;12(1):38. doi: 10.1186/s40035-023-00370-0. Transl Neurodegener. 2023. PMID: 37501056 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous